Sign in
Taking people in FrancePhase 3

Reduced-dose rivaroxaban blood thinner tested in people on dialysis

Tests a lower rivaroxaban dose to prevent clots in adults on hemodialysis.

Key facts

Who runs it
University Hospital, Tours
Where
Tours, FranceSee the 2 sites
Trial code
Registry title
Chronic Anticoagulation With a Reduced Dose Regimen of Rivaroxaban in End-stage Renal Disease Patients
Status
Recruiting
Phase
Phase 3
People taking part
10 people, planned
Started
8 Jan 2025
Expected to end
30 Jan 2027
Type of study
Interventional
Treatments tested
  • Rivaroxaban
Record updated
18 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults who have been on chronic hemodialysis for at least 3 months and have no other need for long-term blood thinners. It tests reduced doses of rivaroxaban.

Age
18 years or older
Sex
All sexes can join
Disease stage
Chronic hemodialysis for at least 3 months
Earlier treatment
Must not be on long-term oral blood thinners; must not take double anti-platelet treatment or aspirin above 160 mg/day

Main reasons for not taking part

  • Any reason for long-term oral blood thinners, such as atrial fibrillation or a mechanical valve
  • Uncontrolled high blood pressure (above 180/110 mmHg)
  • Stroke from a blocked vessel in the last 30 days, or surgery in the last 30 days
  • Past major bleeding without a clear cause, or another high bleeding risk
  • Pregnant or breastfeeding women

This trial only enrols participants on dialysis. The registry sentence this rests on: Chronic hemodialysis patient for at least 3 months,

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • Adult patient ≥ 18 years of age,
  • Chronic hemodialysis patient for at least 3 months,
  • Affiliated or beneficiary of a social security plan,
  • Having signed a written and informed consent

Who cannot take part

  • Ischemic stroke within 30 days prior to inclusion
  • Surgery within 30 days prior to inclusion
  • Patients already participating in an ongoing study or who have participated in a study that ended less than 30 days prior to the inclusion date
  • Any indication for long-term oral anticoagulation (atrial fibrillation, venous thromboembolic disease, mechanical valve prostheses, intracardiac thrombosis, etc.)
  • Uncontrolled hypertension (BP > 180/110 mmHg)
  • High-risk bleeding condition in addition to renal failure (such as known coagulation disorder, thrombocytopenia (< 100G/L), active neoplasia of the digestive or urinary tract, or presence of intracranial vascular malformation)
  • Severe hepatic impairment
  • Contraindication to the administration of an anticoagulant treatment such as anti-phospholipid antibody syndrome
  • Known allergy to rivaroxaban or to one of its excipients (lactose monohydrate)
  • Double anti-platelet aggregation for any reason or an aspirin dose greater than 160 mg/day
  • History of major unprovoked hemorrhage (leading to hospitalization or transfusion) regardless of age
  • Pregnant or breastfeeding women, women of childbearing age without effective contraception
  • Use of strong CYP3A4 inducers, including rifampin, St. John's Wort, carbamazepine, phenytoin, phenobarbital
  • Non-compliant patients
  • Patients under guardianship or conservatorship

Where in France

  • 01-AraucoTours, FranceContact: Annabelle GOUMARDTaking people
  • 02-TOURSTours, FranceContact: Jean-François VALENTINTaking people

About the trial

What the trial wants to find out

Atrial fibrillation is the most frequent cardiac rhythm disorder and its prognosis is essentially marked by the risk of embolic events. Its treatment is based on long-term oral anticoagulant therapy according to the risk of embolic events assessed by risk scores such as the CHA2DS2-Vasc score, but this prescription is associated with a risk of hemorrhagic events that must be taken into consideration when deciding on the treatment for a given patient. There are two categories of validated oral anticoagulant treatments for the prevention of embolic events in atrial fibrillation: antivitamin K agents, which have long been the reference treatment but are restrictive and difficult to use because of a narrow therapeutic window, and direct oral anticoagulants, which are now the first-line treatment but have not been evaluated in phase II and III studies in patients with severe renal failure. End-stage renal disease (clearance <15 mL/min/1.73m2), particularly at the dialysis stage, is a risk factor for cardiovascular disease in its own right, and a significant number of patients develop atrial fibrillation. Given the co-morbidities associated with renal failure, in particular hypertension, patients with renal failure undergoing dialysis and suffering from atrial fibrillation are generally at a higher risk of embolism than patients without renal failure, but also at a higher risk of bleeding. Thus, if the indication for prescribing oral anticoagulant therapy is clear in this population, the associated bleeding complications are also more frequent and more serious in these patients who have regular vascular accesses in the context of hemodialysis. There is thus a real need for reliable therapeutic alternatives with a better benefit/risk ratio than antivitamins K.

Read full original descriptionShow less

Translated with www.DeepL.com/Translator (free version)

The group in the trial

  • RivaroxabanTreatment being tested

    Rivaroxaban 5 mg daily, administered orally, during 3 consecutive days. After a wash-out period of 4 days, Rivaroxaban 10 mg daily, administered orally, during 3 consecutive days. After a wash-out period of 4 days, Rivaroxaban 15 mg daily, administered orally, during 3 consecutive days.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Chronic Anticoagulation in End-stage Renal Disease Patients: Pharmacokinetics and Pharmacodynamic of a Reduced Dose Regimen of Rivaroxaban
Plain-language title
Reduced-dose rivaroxaban blood thinner tested in people on dialysisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
18 June 2026